You are viewing the site in preview mode

Skip to main content

Table 4 Visual acuity (LogMAR) before and after intravitreal injection and management

From: Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes

Case

VA Before IVI

VA After IVI

Management

Last Check VA

1

HM

HM

IV Vanco + zidim + PPV + Silicon

HM

2

0.3

0.3

IV Vanco + zidim + PPV + Silicon

0.3

3

0.4

HM

IVVanco + zidim + PPV + Phaco-IOL + Silicon

1.6

4

0.7

1.0

IV Vanco + zidim + PPV + Silicon

0.8

5

1.3

LP

IV Vanco + zidim + PPV + Phaco + Silicon

1.3

6

1.3

HM

IV Vanco + zidim + PPV + Silicon

0.7

7

0.4

HM

IV Vanco + zidim + PPV + Silicon

1.3

8

0.6

1.3

IV Vanco + zidim

0.6

9

1.0

1.3

IV Vanco + zidim + PPV

1.0

10

0.2

0.6

IV Vanco + zidim + PPV

0.6

11

1.3

HM

IV Vanco + zidim

0.3

12

0.2

0.2

IV Vanco + zidim + PPV

0.1

13

0.6

0.4

IV Vanco + zidim + PPV + Phaco

0.2

  1. VA: Visual Acuity, IVI: Intravitreal injection, HM: Hand motions, LP: Light perception, IV Vanco + zidim: Intravitreal vancomycin and ceftazidime, PPV: Pars plana vitrectomy, Phaco: Phacoemulsification, IOL: Intraocular lens